Location:Room 4, Capital suite (level 3)
The shortage of BCG showed to the urological society that the treatment method depending on one source can cause great difficulty and can even lead to cystectomy.
In the session the speakers wil show that innovation of the treatment for Non Muscle Invasive Bladder Cancer (NMIBC) is on its way.
The psycho-social burden on patients with NMIBC is, compared to other oncological illnesses, a long-lasting burden. Unmet needs have, because of the length of the treatment and follow up, a deep impact.
In this session the speakers will elaborate on these themes.
Participants will gain knowledge about:
-non-muscle invasive bladder cancer (NMIBC)
-risk-stratification of NMIBC
-treatment of NMIBC, more in particular high-risk NMIBC and bladder-preserving strategies
Improvement in treatment of Urothelial Carcinoma of the urinary Bladder (UCB) has led to a larger numbers of survivors living with the impact of treatment and side effects on their Health-Related Quality Of Life (HRQOL). However, methodological limitations and the lack of sensitivity of the HRQOL measures used to assess gender-, age-, and treatment-related differences may limit the generalisability of their outcomes and their utility in clinical settings. A vast body of research identifying patients’ informational and supportive care needs during survivorship has emerged. Research examining unmet needs in UCB patients lags significantly behind that of other cancers both in terms of the adequacy of needs measures and the breadth and depth of published studies on these issues. Our recent studies in UCB patients showed significant unmet informational and supportive care needs that vary across the disease trajectory. This paper will review study results and discuss their implications for UCB research and health care.